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Figure S1. Synthetic scheme and results in the preparation of PDO 19. This compound was 
obtained mixed with the corresponding imine (secondary product). This mixture treated with 
aminoguanidine yield PDO 21. 
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Table S1. Proportions of 7- and 8-Isomers of Studied Compounds. 
 
compound 7:8 isomers ratio
a 
6 50 : 50 
7 55 : 45 
8 50 : 50 
9 53 : 47 
10
 51 : 49 
11 44 : 56 
12 52 : 48 
  
13 65 : 35 
14 59 : 41 
15 56 : 44 
16 55: 45 
17 58 : 42 
18 60 : 40 
  
19 60 : 40
b 
20 65 : 35
b 
21 58 : 42
b 
22
 60 : 40
b 
  
23 56 : 44 
25 50 : 50
b 
a 
Determined by 
1
H-NMR from the isolated products. 
b
 7-fluoro- and 8-
fluoro-isomers. 
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Simulated hypoxia  
a)                                                                                                 b) 
           
Simulated normoxia  
   c)                                                            d) 
 
Figure S2. TLC chromatograms (see Material and methods for experimental conditions) taken after 
30 min of incubation of PDO 12 with different protein fractions and in different gasification 
conditions. Simulated hypoxia: a) Spots without revealed (PDO, orange; phenazine monoxides, 
yellow); b) Run 1 spots visualised by spraying with a solution of p-anisaldehyde:H2SO4(c):EtOH 
(95:4:1) followed by heating. Runs: 1. Incubation with S9 fraction; 2. Control of enzymatic 
fractions; 3. PDO 23; 4. PDO 12; 5. Incubation with cytosolic fraction; 6. Incubation with 
microsomal fraction. Simulated normoxia: c) Spots without revealed (PDO, orange; phenazine 
monoxides, yellow); d) Spots visualised by spraying with a solution of p-
anisaldehyde:H2SO4(c):EtOH (95:4:1) followed by heating. Runs: 1-3. Incubations with cytosolic, 
microsomal, and S9 fractions; 4. PDO 12; 5. PDO 23. 
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b) 
 
 
 
 
Figure S3. Stern–Volmer quenching plot (right) from the fluorescence data with increasing 
concentrations of DNA in PBS (left). a) For toluene blue (reference compound). b) For PDO 7. 
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a)                                                           b) 
  
                     c) 
 
 
 
Figure S4. a) Variation of fluorescence of PDO 6 with increasing concentrations of DNA. b) 
Stern–Volmer quenching plot from the fluorescence data with increasing concentrations of DNA in 
PBS for PDO 6. The red circle point to the region used to determine the Kp (c)). c) Kp 
determination for PDO 6 in the DNA concentrations range 40-200 M. 
 
 
 
 
Kq = 15  3 
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Detailed experimental procedures and spectroscopic characterization of benzofuroxan 
(IV) 
Synthesis of 4-(5-amino-2-fluoro-4-
nitrophenoxy)benzaldehyde. Dried molecular sieves (3 
Å) were loaded into the main chamber of a Soxhlet 
extractor equipment. Then the extractor was placed onto a 
flask containing a mixture of 4,5-difluoro-2-nitroaniline (4.5 mmol), p-hydroxybenzaldehyde (4.1 
mmol), anhydrous potassium carbonate (4.1 mmol), 18-crown-6 (4.1 mmol) and dried toluene (70 
mL). The mixture was heated at reflux during 2.5 h. After that, the toluene was evaporated in vacuo 
and the residue was dissolved in EtOAc (50 mL) and washed with an aqueous solution of sodium 
hydroxide (10 %) (3 × 20 mL). The organic phase was dried over anhydrous Na2SO4 and 
evaporated in vacuo. The formed solid corresponded to the desired product. Green solid (91 %). 
1
H-
NMR (CDCl3+D2O, 400 MHz) δ (ppm): 10.01 (1H, s, H1), 8.04 (1H, d, J= 10.8Hz, H8), 7.94 (2H, 
d, J= 8.6 Hz, H3), 7.21 (2H, d, J= 8.6 Hz, H4), 6.41 (1H, d, J= 6.8 Hz, H11). 
13
C-NMR (CDCl3, 100 
MHz) δ (ppm): 191.8, 160.7, 151.0, 146.5, 137.1, 132.6, 130.1, 127.5, 119.1, 114.5, 108.8. MS, m/z 
(%): 276 (M
.+
, 100), 260 (M
.+
 - 16, 2), 246 (M
.+
 - 30, 10), 230 (M
.+
 - [NO2], 10). 
 
Synthesis of 5-fluoro-6-(4-formylphenoxy)benzo[1,2-
c][1,2,5]oxadiazole (IV). A solution of 4-(5-Amino-2-
fluoro-4-nitrophenoxy)benzaldehyde (4.3 mmol) in 
acetone (19 mL) and glacial acetic acid (12 mL) was 
cooled at 0 
o
C and a solution of sodium nitrite (4.3 mmol) in concentrated hydrochloric acid (1.2 
mL) and water (3.3 mL) was added dropwise. Then the reaction mixture was stirred during 30 min 
at 0 
o
C. After that, a solution of sodium azide (4.3 mmol) and sodium acetate (4.3 mmol) in water 
(1.1 mL) was added dropwise and the reaction mixture was raised to room temperature and stirred 
for 2 h. The acetone was evaporated in vacuo and the residue was dissolved in EtOAc (50 mL) and 
washed with an aqueous solution of sodium hydroxide (10 %) (3 × 20 mL). The organic phase was 
dried over anhydrous Na2SO4 and evaporated in vacuo. The residue was dissolved in toluene (75 
mL) and the solution was heated at reflux for 2 h. The toluene was evaporated in vacuo. The residue 
was purified by chromatography (SiO2, petroleum ether:EtOAc, 8:2) yielding the desired product as 
a yellow solid (71 %). 
1
H-NMR (CDCl3, 400 MHz) δ (ppm): 10.05 (1H, s, H11), 8.01 (2H, d, J= 9.1 
Hz, H9), 7.30 (2H, d, J= 9.0 Hz, H8), 7.45-7.20 (1H, bs, H1), 7.25-7.05 (1H, bs, H4). 
13
C-NMR 
(CDCl3, 100 MHz) δ (ppm): 190.7, 159.4, 159.3, 149.0, 134.3, 132.7, 118.9, 118.4, 113.1. MS, m/z 
(%):274 (M
.+
, 100), 258 (M
.+
 - [O], 15), 228 (M
.+
 - [NO2], 2), 213 (M
.+
 - [N2O2] - [H], 85). 
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Selected NMR spectra 
 
7(8)-Chloro-2-(4-chlorobenzylamino)phenazine 5,10-dioxide (11) 
(7:8 isomers ratio, 44:56) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
CD3OD:D2O (9:1) as solvent. 
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Selected region, aromatics, of the proton NMR spectrum recorded on a Bruker DPX-400 
spectrometer at 298 K and using CD3OD:D2O (9:1) as solvent. 
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7(8)-Bromo-2-(4-methylphenylsulfonylamino)phenazine 5,10-dioxide (12) 
(7:8 isomers ratio, 52:48) 
 
 
Selected region, aromatics, of the proton NMR spectrum recorded on a Bruker DPX-400 
spectrometer at 298 K and using DMSO-d6:D2O (1:1) as solvent. Inset: region of the 
methyl-protons. 
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2-Amino-7(8)-(E-2-phenylethenyl)phenazine 5,10-dioxide (13)  
(7:8 isomers ratio, 65:35) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2SO4 (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2SO4 (9.5:0.5) as solvent. 
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2-Hydroxy-7(8)-(E-2-phenylethenyl)phenazine 5,10-dioxide (14) 
(7:8 isomers ratio, 59:41) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent.. Inset: 
protons that allowed to determine the ratio of isomers. 
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2-Amino-7(8)-[E-2-(4-chlorophenyl)ethenyl)phenazine 5,10-dioxide (15) 
(7:8 isomers ratio, 56:44) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent. 
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7(8)-[E-2-(4-Chlorophenyl)ethenyl)-2-hydroxyphenazine 5,10-dioxide (16) 
(7:8 isomers ratio, 55:45) 
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1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
 
Selected regions, aromatics, of the proton NMR spectrum recorded on a Bruker DPX-400 
spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent. 
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2-Amino-7(8)-fluoro-8(7)-(4-formylphenyloxy)phenazine 5,10-dioxide (19) 
(as mixture of aldehyde and the corresponding imine) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent. 
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7(8)-Fluoro-8(7)-(4-formylphenyloxy)-2-hydroxyphenazine 5,10-dioxide (20) 
(7:8 isomers ratio, 65:35) 
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1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent. 
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7(8)-Bromo-2-(4-methylphenylsulfonylamino)phenazine N
10
-oxide (23) 
(7:8 isomers ratio, 56:44)  
 
 
Selected regions, aromatics, of the proton NMR spectrum recorded on a Bruker DPX-400 
spectrometer at 298 K and using DMSO-d6:D2O (1:1) as solvent. 
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7(8)-Fluoro-8(7)-(4-formylphenyloxy)-2-hydroxyphenazine N-oxide (24) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent. 
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7(8)-fluoro-8(7)-(4-formylphenyloxy)-2-hydroxyphenazine (25) 
(7:8 isomers ratio, 50:50) 
 
 
1
H NMR spectrum recorded on a Bruker DPX-400 spectrometer at 298 K and using 
DMSO-d6:D2O (9.5:0.5) as solvent. 
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Selected regions, aromatics, of the proton and carbon NMR spectra recorded on a Bruker 
DPX-400 spectrometer at 298 K and using DMSO-d6:D2O (9.5:0.5) as solvent. 
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